Cigna CEO Appointment: Evanko to Succeed Cordani
Cigna CEO appointment Brian Evanko will become CEO on July 1, 2026 with Cordani moving to executive chair and guidance reaffirmed, signaling continuity.
KEY TAKEAWAYS
- Evanko will become CEO effective July 1, 2026 and was elected to the board.
- Company reaffirmed 2026 adjusted income from operations of at least $30.25 per share.
- Cordani will become executive chair with a $1 million base salary and $2 million incentive target.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
The Cigna Group (NYSE: CI) announced on March 3, 2026, that Brian C. Evanko will succeed David M. Cordani as chief executive on July 1, 2026, as Cordani moves to executive chair. The company also reaffirmed its 2026 adjusted-income-from-operations outlook.
Evanko Named CEO Effective July 1
Brian C. Evanko, 49, a CFA and 30-year Cigna veteran, currently serves as president and chief operating officer. He oversees Cigna Healthcare and Evernorth Health Services and previously held roles as chief financial officer and CEO of Cigna Healthcare. Evanko was elected to the company’s board in connection with the succession.
David M. Cordani, who has been CEO since 2009, will retire from that role and become executive chair of the board. Under his leadership, customer relationships grew from 46 million to 180 million, and annual revenue increased from $18 billion to $275 billion. Total shareholder return rose by more than 750%. An SEC Form 8-K filed March 3 reported the leadership change as a material event and disclosed that Cordani’s executive-chair compensation includes a $1 million base salary and a $2 million incentive target.
Cordani praised Evanko’s record, saying, "Brian is an exceptional leader and the right person to guide The Cigna Group into its next chapter." The board election and role changes are internal, with no regulatory approvals required.
Guidance Reaffirmed for 2026
Cigna reaffirmed full-year 2026 consolidated adjusted income from operations of at least $30.25 per share (non-GAAP, after-tax). It maintained segment pre-tax adjusted-income targets of at least $6.9 billion for Evernorth and $4.5 billion for Cigna Healthcare. The company defines adjusted income from operations as shareholders’ net income excluding net investment gains or losses, amortization of acquired intangibles, and special items. It noted that forward-looking statements remain subject to risks including healthcare costs, competition, inflation, economic downturns, regulatory changes, and strategic initiatives.
The appointment of an internal successor with extensive operational and financial experience, combined with the immediate reaffirmation of guidance, signals management’s focus on continuity through the CEO transition. For investors assessing transition risk, promoting a longtime insider who already sits on the board and maintaining unchanged targets emphasize steady execution rather than abrupt strategic shifts.
